Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

Completed · Not applicable

Conditions studied: Precancerous Condition

In brief

RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis. PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.

Key facts

Study ID

NCT00879879

Run by

University of South Florida

People needed

20

Starts

2009-03-01

Expected to finish

2012-03-01

Last updated by the study team

2021-02-21

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 21 years
• Diagnosis of idiopathic pulmonary fibrosis
• Patients taking Coumadin and/or N-acetylcysteine may participate in the study
• Baseline forced vital capacity (FVC) must be greater than or equal to 50%
• Baseline 6 minute walk test distance walked must be greater than or equal to 200 meters not requiring greater than 6 lpm of oxygen

You may not qualify if…

• Pregnant, intending to become pregnant or breastfeeding
• Current or previous smoker of cigarettes or marijuana that recently quit within the last 6 months prior to enrollment
• Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker
• Taking losartan or any other angiotensin II receptor blocker
• Baseline systolic blood pressure < 100 mmHg
• Currently taking or has taken immunosuppressant agents within the last month such as azathioprine, cyclophosphamide, colchicine and/or prednisone
• History of lung transplant
• History of kidney failure or liver disease
• Inability to attend clinic visits

Where it is running

• University of Cincinnati — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.